Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2013	Jul. 18, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2
Trading Symbol	nuro
Entity Common Stock, Shares Outstanding		2,636,142
Entity Registrant Name	NeuroMetrix, Inc.
Entity Central Index Key	0001289850
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company

Balance Sheets (USD $)	Jun. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 9,586,435	$ 8,699,478
Accounts receivable, net	562,063	566,451
Inventories	753,944	834,526
Prepaid expenses and other current assets	305,615	462,503
Current portion of deferred costs	6,935	10,108
Total current assets	11,214,992	10,573,066
Fixed assets, net	230,566	293,897
Deferred costs and other long-term assets	3,098	10,484
Total assets	11,448,656	10,877,447
Current liabilities:
Accounts payable	208,498	257,361
Accrued compensation	716,780	647,288
Accrued expenses	1,061,168	948,843
Current portion of deferred revenue	117,930	134,185
Current portion of capital lease obligation	7,283	17,929
Total current liabilities	2,111,659	2,005,606
Deferred revenue, net of current portion	41,225	71,419
Common stock warrants	2,855,209	0
Total liabilities	5,008,093	2,077,025
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock
Common stock, $0.0001 par value; 50,000,000 shares authorized; 2,505,071 and 2,140,871 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively	251	214
Additional paid-in capital	148,632,496	147,393,151
Accumulated deficit	(142,192,188)	(138,592,943)
Total stockholders’ equity	6,440,563	8,800,422
Total liabilities and stockholders’ equity	11,448,656	10,877,447
Convertible Preferred Stock
Stockholders’ equity:
Preferred stock	$ 4	$ 0

Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	2,505,071	2,140,871
Common stock, shares outstanding	2,505,071	2,140,871
Convertible Preferred Stock [Member]
Preferred stock, shares authorized	4,438	0
Preferred stock, issued	4,436.764	0
Preferred stock, outstanding	4,436.764	0

Statements of Operations (USD $)	3 Months Ended		6 Months Ended
Statements of Operations (USD $)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenues	$ 1,160,472	$ 2,205,831	$ 2,561,926	$ 4,287,373
Cost of revenues	501,161	983,350	1,070,945	2,118,294
Gross profit	659,311	1,222,481	1,490,981	2,169,079
Operating expenses:
Research and development	913,847	1,020,726	1,987,266	1,998,792
Sales and marketing	880,218	1,595,642	1,660,059	3,129,743
General and administrative	992,160	1,382,268	2,225,754	2,573,332
Total operating expenses	2,786,225	3,998,636	5,873,079	7,701,867
Loss from operations	(2,126,914)	(2,776,155)	(4,382,098)	(5,532,788)
Interest income	1,394	4,027	3,163	8,325
Warrants offering costs	(376,306)	0	(376,306)	0
Change in fair value of warrant liability	1,155,996	0	1,155,996	0
Net loss	$ (1,345,830)	$ (2,772,128)	$ (3,599,245)	$ (5,524,463)
Net loss per common share applicable to common stockholders, basic and diluted (See Note 3, Net Loss per Common Share)	$ (0.92)	$ (1.32)	$ (1.97)	$ (3.17)
Weighted average number of common shares outstanding, basic and diluted	2,299,463	2,094,487	2,215,658	1,740,325

Statements of Cash Flows (USD $)	6 Months Ended
Statements of Cash Flows (USD $)	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities:
Net loss	$ (3,599,245)	$ (5,524,463)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	79,299	136,566
Stock-based compensation	96,107	157,586
Inventory charges	77,642	258,848
Warrants offering costs	376,306	0
Fair Value Adjustment of Warrants	(1,155,996)	0
Changes in operating assets and liabilities:
Accounts receivable	4,388	391,044
Inventories	2,940	427,702
Prepaid expenses and other current assets	156,888	30,474
Accounts payable	(48,863)	(164,273)
Accrued expenses and compensation	383,263	(373,513)
Deferred revenue, deferred costs, and other	(35,890)	32,432
Net cash used in operating activities	(3,663,161)	(4,627,597)
Cash flows from investing activities:
Purchases of fixed assets	(15,968)	(28,892)
Release of restricted cash	0	229,500
Net cash (used in) provided by investing activities	(15,968)	200,608
Cash flows from financing activities:
Net proceeds from issuance of stock and equity	4,576,732	7,471,370
Payments on capital lease	(10,646)	(10,003)
Net cash provided by financing activities	4,566,086	7,461,367
Net increase in cash and cash equivalents	886,957	3,034,378
Cash and cash equivalents, beginning of period	8,699,478	10,290,446
Cash and cash equivalents, end of period	9,586,435	13,324,824
Supplemental disclosure of cash flow information:
Common stock issued to settle incentive compensation obligation	285,296	0
Warrants issued under Securities Purchase Agreement recorded as a non-current liability	4,011,205	0
Common stock issued in exchange for warrants	$ 0	$ 127,885

Business and Basis of Presentation

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Business and Basis of Presentation

1.	Business and Basis of Presentation

Our Business-An Overview

NeuroMetrix, Inc., or the Company, a Delaware corporation, was founded in June 1996. The Company is a medical device company focused on the neurological complications of diabetes. The Company believes that its substantial experience in developing medical devices to stimulate and measure peripheral nerve function uniquely position it to address unmet medical needs related to diabetic neuropathy. Neuropathy is a common and serious, often painful, complication of diabetes that may lead to foot ulcers and limb amputation. The Company has over a decade of experience in neuropathy detection, starting with approval in 1998 by the United States Food and Drug Administration, or FDA, of the NC-stat System, a point-of-care device for the performance of general purpose nerve conduction studies.

In the first quarter of 2013, the Company completed product development and launched the SENSUS™ Pain Management System, or SENSUS, which is designed for relief of chronic, intractable pain. The Company believes this product will be attractive to pain medicine physicians, neurologists, endocrinologists, podiatrists, primary care physicians, and other physicians that are challenged with trying to manage pain in their patients with painful diabetic neuropathy, or PDN and other forms of neuropathic pain. The Company also markets the NC-stat^® DPNCheck^® device, which is a fast, accurate, and quantitative nerve conduction test that is used to evaluate systemic neuropathies such as diabetic peripheral neuropathy, or DPN. NC-stat DPNCheck is designed to be used by endocrinologists, podiatrists, primary care physicians and other clinicians at the point-of-care to objectively detect, stage, and monitor DPN. Sales efforts for NC-stat DPNCheck are currently targeted at opportunities in the managed care market. The Company’s historical neurodiagnostic business is based on the ADVANCE™ NCS/EMG System, or the ADVANCE System, which is a comprehensive platform for the performance of traditional nerve conduction studies and invasive electromyography procedures and which is primarily used in physician offices and clinics. While the ADVANCE System contributes the majority of the Company’s revenues, the Company is not actively managing the ADVANCE business for growth.

On June 4, 2013, the Company entered into a Securities Purchase Agreement, as amended (the “Purchase Agreement”), providing for the issuance of (i) 248,147 shares of common stock at a price of $2.095 per share, (ii) 1,066.254 shares of Series A-1 convertible preferred stock (the “Series A-1 Preferred Stock”) at a price of $1,000 per share, (iii) 3,370.510 shares of Series A-2 convertible preferred stock (the “Series A-2 Preferred Stock” and together with the Series A-1 Preferred Stock, the “Preferred Stock”) at a price of $1,000 per share, and (iv) five year warrants to purchase up to 2,365,934 shares of common stock with an exercise price of $2.00 per share (the “2013 Offering”). Each share of Preferred Stock is convertible into 477.327 shares of common stock, subject to adjustment, at any time at the option of the holder. The 2013 Offering resulted in approximately $5.0 million in gross proceeds, before deducting placement agent fees and other expenses. Net proceeds from the 2013 Offering were approximately $4.6 million. See Note 10, Stockholders’ Equity, for further details.

The Company held cash and cash equivalents of $ 9.6 million as of June 30, 2013. The Company believes that these resources and the cash to be generated from expected product sales will be sufficient to meet its projected operating requirements into the third quarter of 2014. The Company continues to face significant challenges and uncertainties and, as a result, the Company’s available capital resources may be consumed more rapidly than currently expected due to (a) decreases in sales of the Company’s products and the uncertainty of future revenues from new products; (b) changes the Company may make to the business that affect ongoing operating expenses; (c) changes the Company may make in its business strategy; (d) regulatory developments affecting the Company’s existing products and delays in the FDA approval process for products under development; (e) changes the Company may make in its research and development spending plans; and (f) other items affecting the Company’s forecasted level of expenditures and use of cash resources. Accordingly, the Company will need to raise additional funds to support its operating and capital needs in the third quarter of 2014 and beyond. The Company may attempt to obtain additional funding through public or private financing, collaborative arrangements with strategic partners, or through additional credit lines or other debt financing sources to increase the funds available to fund operations. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity or debt securities to raise additional funds, its existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies, or grant licenses on terms that are not favorable to the Company. Without additional funds, the Company may be forced to delay, scale back or eliminate some of its sales and marketing efforts, research and development activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue its operations. If any of these events occurs, the Company’s ability to achieve its development and commercialization goals would be adversely affected.

Certain prior period amounts have been adjusted to reflect the Company's 1-for-6 reverse stock split of its common stock completed on February 15, 2013. See Note 11, Reverse Stock Split, for further details.

Unaudited Interim Financial Statements

The accompanying unaudited balance sheet as of June 30, 2013, unaudited statements of operations for the quarters and six months ended June 30, 2013 and 2012 and the unaudited statements of cash flows for the six months ended June 30, 2013 and 2012 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair statement of the Company’s financial position and operating results. Operating results for the quarter and six months ended June 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on February 25, 2013 (File No. 001-33351), or the Company’s 2012 Form 10-K. The accompanying balance sheet as of December 31, 2012 has been derived from audited financial statements prepared at that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

Revenues

The Company recognizes revenue when the following criteria have been met: persuasive evidence of an arrangement exists, delivery has occurred and risk of loss has passed, the seller’s price to the buyer is fixed or determinable, and collection is reasonably assured.

Revenues associated with the sale of the ADVANCE devices to customers and distributors are recognized upon shipment, provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, product returns are reasonably estimable, and no continuing obligations exist. The revenues from the sale of an ADVANCE communication hub together with access to NeuroMetrix information systems are considered one unit of accounting and deferred and recognized on a straight-line basis over the estimated period of time that the Company provides the service associated with the information systems of three years. The resulting deferred revenue and deferred costs are presented as separate line items on the accompanying balance sheet. Revenues related to extended service agreements for the devices are recognized ratably over the term of the extended service agreement.

Revenues associated with the sale of the SENSUS and NC-stat DPNCheck devices are recognized upon shipment, provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, product returns are reasonably estimable, and no continuing obligations exist.

Revenues also include sales of consumables, including single use nerve specific electrodes and other accessories. These revenues are recognized upon shipment provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, and product returns are reasonably estimable.

When multiple elements are contained in a single arrangement, the Company allocates revenue between the elements based on their relative selling prices. The Company determines selling price using vendor specific objective evidence, or VSOE, if it is available, third-party evidence, or TPE, if VSOE is not available, and best estimate of selling price, or BESP, if neither VSOE nor TPE are available. The Company generally expects that it will not be able to establish TPE due to the nature of the markets in which it competes, and, as such, it will typically determine selling price using VSOE or if not available, BESP. The objective of BESP is to determine the selling price of a deliverable on a standalone basis. The Company’s determination of BESP involves a weighting of several factors based on the specific facts and circumstances of an arrangement. Specifically, the Company considers the cost to produce the deliverable, the anticipated margin on that deliverable, the selling price and profit margin for similar parts, its ongoing pricing strategy, the value of any enhancements that have been built into the deliverable, and the characteristics of the varying markets in which the deliverable is sold.

Revenue recognition involves judgments, including assessments of expected returns and expected customer relationship periods. The Company analyzes various factors, including a review of specific transactions, its historical returns, average customer relationship periods, customer usage, customer balances, and market and economic conditions. Changes in judgments or estimates on these factors could materially impact the timing and amount of revenues and costs recognized. Should market or economic conditions deteriorate, the Company’s actual return or bad debt experience could exceed its estimate.

Certain product sales are made with a 30-day right of return. Since the Company can reasonably estimate future returns, it recognizes revenues associated with product sales that contain a right of return upon shipment and at the same time it records a sales return reserve, which reduces revenue and accounts receivable by the amount of estimated returns.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.

Recent Accounting Pronouncements

There have been no recent accounting pronouncements or changes in accounting pronouncements since the recent accounting pronouncements described in the Company's 2012 Form 10-K that are of significance to the Company.

Net Loss Per Common Share

6 Months Ended

Jun. 30, 2013

Earnings Per Share [Abstract]

Net Loss Per Common Share

3.	Net Loss Per Common Share

Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not considered outstanding for purposes of calculating basic net income per share. Diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period plus the dilutive effect of the weighted average number of outstanding instruments such as options, warrants, restricted stock, and preferred stock. Because the Company has reported a net loss for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. Therefore, in calculating net loss per share amounts, shares underlying the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net income per common share because their effect was anti-dilutive for each of the periods presented:

	Quarters Ended June 30,			Six Months Ended June 30,
	2013	2012		2013	2012
Options	50,757		54,657	50,962		55,385
Warrants	1,457,936		781,954	1,121,813		700,694
Unvested restricted stock	20,318		38,817	27,271		24,623
Convertible preferred stock	605,082		—	304,212		—
Total	2,134,093		875,428	1,504,258		780,702

The Beneficial Conversion Feature, or BCF, recorded in the 2013 Offering has been recognized as a deemed dividend attributable to the Preferred Stock and is reflected as an adjustment in the calculation of earnings per share. See Note 10, Stockholders’ Equity, for further details.

Net loss per common share was determined as follows:

	Quarters Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Net loss	$	(1,345,830)	$	(2,772,128)	$	(3,599,245)	$	(5,524,463)
Deemed dividend attributable to preferred stockholders in connection with embedded conversion features		(766,872)		—		(766,872)		—
Net loss applicable to common stockholders	$	(2,112,702)	$	(2,772,128)	$	(4,366,117)	$	(5,524,463)

Net loss per common share applicable to common stockholders, basic and diluted	$	(0.92)	$	(1.32)	$	(1.97)	$	(3.17)

Weighted average number of common shares outstanding, basic and diluted		2,299,463		2,094,487		2,215,658		1,740,325

Common Stock

6 Months Ended

Jun. 30, 2013

Stockholders' Equity Note [Abstract]

Common Stock

4.	Common Stock

On June 4, 2013, the Company entered into a Securities Purchase Agreement, pursuant to which it issued 248,147 shares of common stock at a price of $2.095 per share. See Note 10, Stockholders’ Equity, for further details.

In March 2013, the Company awarded certain executives an aggregate of 119,370 shares of fully vested common stock with a value of $285,300 in settlement of 2012 incentive compensation obligations. The shares issued reflected the $2.39 closing price of the Company’s common stock as reported on the NASDAQ Capital Market on March 4, 2013.

On February 13, 2012, the Company completed a public offering of 1,421,735 Units at a price of $6.00 per Unit (the “2012 Offering”). Each Unit consisted of one share of the Company’s common stock and one warrant to purchase one half of a share of the Company’s common stock. The Company issued 1,421,735 shares of common stock and warrants to purchase 781,955 shares of common stock and received proceeds, net of discounts, commissions and expenses, of approximately $7.4 million. See Note 10, Stockholders’ Equity, for further details.

In March 2012, the Company issued 23,127 shares of its common stock in satisfaction of the Company’s obligation to redeem certain warrants issued by the Company pursuant to Securities Purchase Agreements dated as of September 8, 2009. No cash was paid to redeem the warrants.

Accrued Compensation and Expenses

6 Months Ended

Jun. 30, 2013

Payables and Accruals [Abstract]

Accrued Compensation and Expenses

6.	Accrued Compensation and Expenses

Accrued compensation includes $429,178 of severance incurred in the second quarter of 2013. No severance payments were made during the period. There were no restructuring charges or payments in the six months ended June 30, 2012. There were no severance charges accrued as of December 31, 2012.

Accrued expenses consist of the following:

	June 30, 2013		December 31, 2012

Technology fees	$	450,000	$	450,000
Professional services		194,576		248,759
Clinical study obligations		104,000		24,490
Sales taxes		33,334		62,385
Supplier obligations		—		105,132
Other		279,258		58,077
	$	1,061,168	$	948,843

Commitments and Contingencies

6 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

7.	Commitments and Contingencies

Operating Lease

The Company leases office and engineering laboratory space in Waltham, Massachusetts. In June 2013, the lease term was extended through March 31, 2015. Base rent for the period July 2013 through March 2015 is $52,917 per month.

Fair Value Measurements

6 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

Fair Value Measurements

8.	Fair Value Measurements

The Fair Value Measurements and Disclosures topic of the Financial Accounting Standards Board, Accounting Standards Codification (the “Codification”) defines fair value, establishes a framework for measuring fair value in applying generally accepted accounting principles, and expands disclosures about fair value measurements. This Codification topic identifies two kinds of inputs that are used to determine the fair value of assets and liabilities: observable and unobservable. Observable inputs are based on market data or independent sources while unobservable inputs are based on the Company’s own market assumptions. Once inputs have been characterized, this Codification topic requires companies to prioritize the inputs used to measure fair value into one of three broad levels. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values identified by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values identified by Level 3 inputs are unobservable data points and are used to measure fair value to the extent that observable inputs are not available. Unobservable inputs reflect the Company’s own assumptions about the assumptions that market participants would use at pricing the asset or liability.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques it utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates, and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

			Fair Value Measurements at June 30, 2013 Using
	June 30, 2013		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	4,193,007	$	4,193,007	$	—	$	—
Total	$	4,193,007	$	4,193,007	$	—	$	—

Liabilities:
Common stock warrants	$	2,855,209	$	—	$	—	$	2,855,209
Total	$	2,855,209	$	—	$	—	$	2,855,209

			Fair Value Measurements at December 31, 2012 Using
	December 31, 2012		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	519,242	$	519,242	$	—	$	—
Total	$	519,242	$	519,242	$	—	$	—

Due to the lack of market quotes relating to our common stock warrants, the fair value of the common stock warrants was determined at June 30, 2013 using the Black-Scholes model, which is based on Level 3 inputs. As of June 30, 2013, inputs used in the Black-Scholes model include our stock price as of that date of $2.00, exercise price of $2.00, expected volatility of 74.1%, risk free interest rate of 1.41%, expected term of approximately four years and 11 months, and no dividends. The assumptions used may change as the underlying sources of these assumptions and market conditions change. Based on this calculation, the Company recorded a gain of $1.1 million during the quarter ended June 30, 2013, resulting in a common stock warrants liability of $2.9 million at June 30, 2013. The Company did not have any financial liabilities carried at fair value as of December 31, 2012.

The following table provides a summary of changes in the fair value of the Company's Level 3 financial liabilities for the six month period ended June 30, 2013:

Balance at December 31, 2012	$	—
Initial fair value of warrants		4,011,205
Change in fair value of warrant liability		(1,155,996)
Balance at June 30, 2013	$	2,855,209

Credit Facility

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

Credit Facility

9.	Credit Facility

The Company is party to a Loan and Security Agreement, or the Credit Facility, with a bank. As of June 30, 2013, the Credit Facility permitted the Company to borrow up to $2.5 million on a revolving basis. Prior to its amendment on January 28, 2013, the amount of the Credit Facility was set at $7.5 million. The amended Credit Facility expires on January 31, 2014. Amounts borrowed under the Credit Facility will bear interest equal to the prime rate plus 0.5%. Any borrowings under the Credit Facility will be collateralized by the Company’s cash, accounts receivable, inventory, and equipment. The Credit Facility includes traditional lending and reporting covenants. These include certain financial covenants applicable to liquidity that are to be maintained by the Company. As of June 30, 2013 and December 31, 2012, the Company was in compliance with these covenants and had not borrowed any funds under the Credit Facility. Of the Credit Facility limit, $225,000 is restricted to support a letter of credit issued in favor of the Company’s landlord in the lease of its facilities in Waltham, Massachusetts. Consequently, the amount available for borrowing under the Credit Facility as of June 30, 2013 was $2,275,000.

Stockholders' Equity

6 Months Ended

Jun. 30, 2013

Stockholders' Equity Note [Abstract]

Stockholders’ Equity

10.

Stockholders’ Equity

On June 4, 2013, the Company entered into a Purchase Agreement providing for the issuance of (i) 248,147 shares of common stock at a price of $2.095 per share, (ii) 1,066.254 shares of Series A-1 Preferred Stock at a price of $1,000 per share, (iii) 3,370.510 shares of Series A-2 Preferred Stock at a price of $1,000 per share, and (iv) five year warrants to purchase up to 2,365,934 shares of common stock with an exercise price of $2.00 per share. The 2013 Offering resulted in approximately $5.0 million in gross proceeds, before deducting placement agent fees and other expenses. Net proceeds from the 2013 Offering were approximately $4.6 million.

The shares of Preferred Stock have a stated value of $1,000 and are convertible at the option of the holder into the number of shares of common stock determined by dividing the stated value by the initial conversion price of $2.095, which is subject to adjustment as provided in each Certificate of Designation for the Preferred Stock. The Preferred Stock has no dividend rights, liquidation preference or other preferences over common stock and has no voting rights except as provided in each Certificate of Designation for the Preferred Stock and as required by law. The warrants to purchase 2,365,934 shares of common stock are exercisable immediately, have a five-year term, and a per share exercise price of $2.00.

The terms and conditions of the Preferred Stock were evaluated based on the guidance of the Derivatives and Hedging topic of the Codification to determine if the conversion feature was an embedded derivative requiring bifurcation. It was concluded that bifurcation was not required because the conversion feature is clearly and closely related to the Preferred Stock. The conversion price at which shares of Preferred Stock are convertible into shares of common stock was determined to be lower than the fair value of common stock at the date of the Purchase Agreement. This “in-the-money” conversion feature, or BCF, requires separate recognition and measurement of its intrinsic value (i.e., the amount of the increase in value that holders of Preferred Stock would realize upon conversion based on the value of the conversion shares on the date of the Purchase Agreement). The BCF measurement totaled $766,900, an amount limited by the transaction proceeds which had been allocated to the Preferred Stock. Because there is not a stated redemption date for the shares of Preferred Stock, the BCF was recognized as a deemed dividend attributable to the Preferred Stock and is reflected as an adjustment in the calculation of earnings per share.

The warrants issued in connection with the 2013 Offering are within the scope of the Derivatives and Hedging topic of the Codification. This Codification topic requires issuers to classify as liabilities (or assets under certain circumstances) financial instruments which require an issuer to settle in registered shares. As the warrants are required to be settled in registered shares when exercised, the Company has reflected the warrants as a liability in the balance sheet. The fair value of the warrants at the date of the 2013 Offering was estimated at $4.0 million using a Black-Scholes model with the following assumptions: stock price of $2.60, exercise price of $2.00, expected volatility of 73.6%, risk free interest rate of 1.05%, expected term of five years, and no dividends. The warrants were revalued at June 30, 2013 using the same Black-Scholes model, and a $1.1 million decrease in the fair value of the warrants at that date was recognized in the Company's statement of operations for the quarter ended June 30, 2013. The warrants liability was reflected in the balance sheet at June 30, 2013 in the amount of $2.9 million. The Company will continue to revalue unexercised warrants at each reporting period over the life of the warrants using the Black-Scholes model and the changes in the fair value of the warrants will be recognized in the Company's statement of operations.

On July 8, 2013, 266.564 shares of Series A-1 Preferred Stock were converted into 127,238 shares of the Company’s common stock and 10.475 shares of Series A-2 Preferred Stock were converted into 5,000 shares of the Company’s common stock.

On February 13, 2012, the Company completed the 2012 Offering, which included 1,421,735 Units at a price of $6.00 per Unit. Each Unit consisted of one share of the Company’s common stock and one warrant to purchase one half of a share of the Company’s common stock. The Company issued 1,421,735 shares of common stock and warrants to purchase 710,868 shares of common stock and received proceeds, net of discounts, commissions and expenses, of approximately $7.4 million. Each warrant entitles the holder to purchase at any time during the period commencing 180 days after the date of the 2012 Offering until the date five years following the closing date of the 2012 Offering, one half of a share of the Company’s common stock. Two warrants would need to be exercised to acquire one share of the Company’s common stock at an exercise price of $6.90 (115% of the aggregate price of the 2012 Offering for a Unit). In addition, the placement agent for the 2012 Offering was issued warrants to purchase 71,087 shares of common stock (equal to 5.0% of the number of shares of common stock included in the Units sold in the 2012 Offering) at an exercise price of $7.50 per share (125% of the aggregate price for a Unit). The placement agent’s warrants became exercisable one year after the date of issuance and will expire on the fifth anniversary of the effectiveness of the registration statement related to the 2012 Offering.

The fair value of the warrants issued in the 2012 Offering was estimated at $2.4 million using a Black-Scholes model with the following assumptions: expected volatility of 73.5%, risk free interest rate of 0.85%, expected term of five years, and no dividends. The volatility assumption is based on weekly historical volatility during the time period that corresponds to the expected option term, a review of comparable medical device companies, and expected future stock price volatility. The relative fair value of the warrants was recorded as equity.

Reverse Stock Split

6 Months Ended

Jun. 30, 2013

Reverse Stock Split [Abstract]

Reverse Stock Split

11.

Reverse Stock Split

On February 15, 2013, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, to effect a 1-for-6 reverse stock split of its common stock. This action had previously been approved by the Company’s stockholders at a special meeting of stockholders held on December 7, 2012 and was intended to address the Company’s deficiency in compliance with the minimum bid listing requirements of the NASDAQ Stock Market. As a result of the reverse stock split, every six shares of the Company’s pre-reverse split common stock were combined and reclassified into one share of its common stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise would have been entitled to receive a fractional share in connection with the reverse stock split received a cash payment in lieu thereof. The par value and other terms of the common stock were not affected by the reverse stock split.

The Company’s shares outstanding immediately prior to the reverse stock split totaled 12,845,228. These were adjusted to 2,140,871 shares outstanding as a result of the reverse stock split. The Company’s common stock began trading at its post-reverse stock split price at the beginning of trading on February 19, 2013. Share, per share, and stock option amounts for all periods presented within this quarterly report on Form 10-Q and the amounts for common stock and additional paid-in capital have been retroactively adjusted to reflect the reverse stock split.

On March 5, 2013, the Company received a letter from The NASDAQ Stock Market indicating that it had regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. The Company’s common stock continues to be listed on The NASDAQ Capital Market.

Business and Basis of Presentation (Policies)	6 Months Ended
Business and Basis of Presentation (Policies)	Jun. 30, 2013
Accounting Policies [Abstract]
Our Business-An Overview	Our Business-An Overview NeuroMetrix, Inc., or the Company, a Delaware corporation, was founded in June 1996. The Company is a medical device company focused on the neurological complications of diabetes. The Company believes that its substantial experience in developing medical devices to stimulate and measure peripheral nerve function uniquely position it to address unmet medical needs related to diabetic neuropathy. Neuropathy is a common and serious, often painful, complication of diabetes that may lead to foot ulcers and limb amputation. The Company has over a decade of experience in neuropathy detection, starting with approval in 1998 by the United States Food and Drug Administration, or FDA, of the NC-stat System, a point-of-care device for the performance of general purpose nerve conduction studies. In the first quarter of 2013, the Company completed product development and launched the SENSUS™ Pain Management System, or SENSUS, which is designed for relief of chronic, intractable pain. The Company believes this product will be attractive to pain medicine physicians, neurologists, endocrinologists, podiatrists, primary care physicians, and other physicians that are challenged with trying to manage pain in their patients with painful diabetic neuropathy, or PDN and other forms of neuropathic pain. The Company also markets the NC-stat^® DPNCheck^® device, which is a fast, accurate, and quantitative nerve conduction test that is used to evaluate systemic neuropathies such as diabetic peripheral neuropathy, or DPN. NC-stat DPNCheck is designed to be used by endocrinologists, podiatrists, primary care physicians and other clinicians at the point-of-care to objectively detect, stage, and monitor DPN. Sales efforts for NC-stat DPNCheck are currently targeted at opportunities in the managed care market. The Company’s historical neurodiagnostic business is based on the ADVANCE™ NCS/EMG System, or the ADVANCE System, which is a comprehensive platform for the performance of traditional nerve conduction studies and invasive electromyography procedures and which is primarily used in physician offices and clinics. While the ADVANCE System contributes the majority of the Company’s revenues, the Company is not actively managing the ADVANCE business for growth. On June 4, 2013, the Company entered into a Securities Purchase Agreement, as amended (the “Purchase Agreement”), providing for the issuance of (i) 248,147 shares of common stock at a price of $2.095 per share, (ii) 1,066.254 shares of Series A-1 convertible preferred stock (the “Series A-1 Preferred Stock”) at a price of $1,000 per share, (iii) 3,370.510 shares of Series A-2 convertible preferred stock (the “Series A-2 Preferred Stock” and together with the Series A-1 Preferred Stock, the “Preferred Stock”) at a price of $1,000 per share, and (iv) five year warrants to purchase up to 2,365,934 shares of common stock with an exercise price of $2.00 per share (the “2013 Offering”). Each share of Preferred Stock is convertible into 477.327 shares of common stock, subject to adjustment, at any time at the option of the holder. The 2013 Offering resulted in approximately $5.0 million in gross proceeds, before deducting placement agent fees and other expenses. Net proceeds from the 2013 Offering were approximately $4.6 million. See Note 10, Stockholders’ Equity, for further details. The Company held cash and cash equivalents of $ 9.6 million as of June 30, 2013. The Company believes that these resources and the cash to be generated from expected product sales will be sufficient to meet its projected operating requirements into the third quarter of 2014. The Company continues to face significant challenges and uncertainties and, as a result, the Company’s available capital resources may be consumed more rapidly than currently expected due to (a) decreases in sales of the Company’s products and the uncertainty of future revenues from new products; (b) changes the Company may make to the business that affect ongoing operating expenses; (c) changes the Company may make in its business strategy; (d) regulatory developments affecting the Company’s existing products and delays in the FDA approval process for products under development; (e) changes the Company may make in its research and development spending plans; and (f) other items affecting the Company’s forecasted level of expenditures and use of cash resources. Accordingly, the Company will need to raise additional funds to support its operating and capital needs in the third quarter of 2014 and beyond. The Company may attempt to obtain additional funding through public or private financing, collaborative arrangements with strategic partners, or through additional credit lines or other debt financing sources to increase the funds available to fund operations. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity or debt securities to raise additional funds, its existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies, or grant licenses on terms that are not favorable to the Company. Without additional funds, the Company may be forced to delay, scale back or eliminate some of its sales and marketing efforts, research and development activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue its operations. If any of these events occurs, the Company’s ability to achieve its development and commercialization goals would be adversely affected. Certain prior period amounts have been adjusted to reflect the Company's 1-for-6 reverse stock split of its common stock completed on February 15, 2013. See Note 11, Reverse Stock Split, for further details.
Unaudited Interim Financial Statements	Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of June 30, 2013, unaudited statements of operations for the quarters and six months ended June 30, 2013 and 2012 and the unaudited statements of cash flows for the six months ended June 30, 2013 and 2012 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair statement of the Company’s financial position and operating results. Operating results for the quarter and six months ended June 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on February 25, 2013 (File No. 001-33351), or the Company’s 2012 Form 10-K. The accompanying balance sheet as of December 31, 2012 has been derived from audited financial statements prepared at that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America.
Revenues	Revenues The Company recognizes revenue when the following criteria have been met: persuasive evidence of an arrangement exists, delivery has occurred and risk of loss has passed, the seller’s price to the buyer is fixed or determinable, and collection is reasonably assured. Revenues associated with the sale of the ADVANCE devices to customers and distributors are recognized upon shipment, provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, product returns are reasonably estimable, and no continuing obligations exist. The revenues from the sale of an ADVANCE communication hub together with access to NeuroMetrix information systems are considered one unit of accounting and deferred and recognized on a straight-line basis over the estimated period of time that the Company provides the service associated with the information systems of three years. The resulting deferred revenue and deferred costs are presented as separate line items on the accompanying balance sheet. Revenues related to extended service agreements for the devices are recognized ratably over the term of the extended service agreement. Revenues associated with the sale of the SENSUS and NC-stat DPNCheck devices are recognized upon shipment, provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, product returns are reasonably estimable, and no continuing obligations exist. Revenues also include sales of consumables, including single use nerve specific electrodes and other accessories. These revenues are recognized upon shipment provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, and product returns are reasonably estimable. When multiple elements are contained in a single arrangement, the Company allocates revenue between the elements based on their relative selling prices. The Company determines selling price using vendor specific objective evidence, or VSOE, if it is available, third-party evidence, or TPE, if VSOE is not available, and best estimate of selling price, or BESP, if neither VSOE nor TPE are available. The Company generally expects that it will not be able to establish TPE due to the nature of the markets in which it competes, and, as such, it will typically determine selling price using VSOE or if not available, BESP. The objective of BESP is to determine the selling price of a deliverable on a standalone basis. The Company’s determination of BESP involves a weighting of several factors based on the specific facts and circumstances of an arrangement. Specifically, the Company considers the cost to produce the deliverable, the anticipated margin on that deliverable, the selling price and profit margin for similar parts, its ongoing pricing strategy, the value of any enhancements that have been built into the deliverable, and the characteristics of the varying markets in which the deliverable is sold. Revenue recognition involves judgments, including assessments of expected returns and expected customer relationship periods. The Company analyzes various factors, including a review of specific transactions, its historical returns, average customer relationship periods, customer usage, customer balances, and market and economic conditions. Changes in judgments or estimates on these factors could materially impact the timing and amount of revenues and costs recognized. Should market or economic conditions deteriorate, the Company’s actual return or bad debt experience could exceed its estimate. Certain product sales are made with a 30-day right of return. Since the Company can reasonably estimate future returns, it recognizes revenues associated with product sales that contain a right of return upon shipment and at the same time it records a sales return reserve, which reduces revenue and accounts receivable by the amount of estimated returns.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements There have been no recent accounting pronouncements or changes in accounting pronouncements since the recent accounting pronouncements described in the Company's 2012 Form 10-K that are of significance to the Company.

Net Loss Per Common Share (Tables)

6 Months Ended

Jun. 30, 2013

Earnings Per Share [Abstract]

Schedule of antidilutive securities excluded from computation of earnings per share

in calculating net loss per share amounts, shares underlying the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net income per common share because their effect was anti-dilutive for each of the periods presented:

	Quarters Ended June 30,			Six Months Ended June 30,
	2013	2012		2013	2012
Options	50,757		54,657	50,962		55,385
Warrants	1,457,936		781,954	1,121,813		700,694
Unvested restricted stock	20,318		38,817	27,271		24,623
Convertible preferred stock	605,082		—	304,212		—
Total	2,134,093		875,428	1,504,258		780,702

Determination of net loss per common share

Net loss per common share was determined as follows:

	Quarters Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Net loss	$	(1,345,830)	$	(2,772,128)	$	(3,599,245)	$	(5,524,463)
Deemed dividend attributable to preferred stockholders in connection with embedded conversion features		(766,872)		—		(766,872)		—
Net loss applicable to common stockholders	$	(2,112,702)	$	(2,772,128)	$	(4,366,117)	$	(5,524,463)

Net loss per common share applicable to common stockholders, basic and diluted	$	(0.92)	$	(1.32)	$	(1.97)	$	(3.17)

Weighted average number of common shares outstanding, basic and diluted		2,299,463		2,094,487		2,215,658		1,740,325

Accrued Compensation and Expenses (Tables)

6 Months Ended

Jun. 30, 2013

Payables and Accruals [Abstract]

Accrued Expenses

Accrued expenses consist of the following:

	June 30, 2013		December 31, 2012

Technology fees	$	450,000	$	450,000
Professional services		194,576		248,759
Clinical study obligations		104,000		24,490
Sales taxes		33,334		62,385
Supplier obligations		—		105,132
Other		279,258		58,077
	$	1,061,168	$	948,843

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates, and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

			Fair Value Measurements at June 30, 2013 Using
	June 30, 2013		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	4,193,007	$	4,193,007	$	—	$	—
Total	$	4,193,007	$	4,193,007	$	—	$	—

Liabilities:
Common stock warrants	$	2,855,209	$	—	$	—	$	2,855,209
Total	$	2,855,209	$	—	$	—	$	2,855,209

			Fair Value Measurements at December 31, 2012 Using
	December 31, 2012		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	519,242	$	519,242	$	—	$	—
Total	$	519,242	$	519,242	$	—	$	—

Fair Value, Liabilities Measured on Recurring Basis

The following table provides a summary of changes in the fair value of the Company's Level 3 financial liabilities for the six month period ended June 30, 2013:

Balance at December 31, 2012	$	—
Initial fair value of warrants		4,011,205
Change in fair value of warrant liability		(1,155,996)
Balance at June 30, 2013	$	2,855,209

Business and Basis of Presentation - Additional Information (Detail) (USD $)	0 Months Ended			6 Months Ended						0 Months Ended
	Jun. 04, 2013	Feb. 15, 2013	Feb. 13, 2012	Jun. 30, 2012	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Jul. 08, 2013 Series A One Convertible Preferred Stock	Jun. 04, 2013 Series A One Convertible Preferred Stock	Jun. 04, 2013 Series A Two Convertible Preferred Stock	Jul. 08, 2013 Series A Two Convertible Preferred Stock
Organization And Basis Of Presentation [Line Items]
Incorporation date				1996-06
Stock issued during period, shares, other	248,147
Share price	$ 2.095				$ 2.00
Preferred stock, issued								266,564	1,066.254	3,370.51	10.475
Preferred stock, par value					$ 0.001	$ 0.001			$ 1,000	$ 1,000
Class of warrant or right, Exercise price of warrants or rights									$ 2.00	$ 2
Gross proceeds from issuance or sale of equity	$ 5,000,000
Proceeds from issuance or sale of equity	4,600,000		7,400,000
Cash and cash equivalents				$ 13,324,824	$ 9,586,435	$ 8,699,478	$ 10,290,446
Stockholders equity note reverse stock split conversion ratio		1-for-6
Shares of common stock issuable upon exercise of warrants			781,955							2,365,934
Conversion of preferred stock into common shares										477.327

Determination of net loss per common share (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Determination of net loss per common share [Line Items]
Net loss	$ (1,345,830)	$ (2,772,128)	$ (3,599,245)	$ (5,524,463)
Deemed dividend attributable to preferred stockholders in connection with embedded conversion features	(766,872)	0	(766,872)	0
Net loss applicable to common stockholders	$ (2,112,702)	$ (2,772,128)	$ (4,366,117)	$ (5,524,463)
Net loss per common share applicable to common stockholders, basic and diluted	$ (0.92)	$ (1.32)	$ (1.97)	$ (3.17)
Weighted average number of common shares outstanding, basic and diluted	2,299,463	2,094,487	2,215,658	1,740,325

Common Stock - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended
Common Stock - Additional Information (Detail) (USD $)	Jun. 04, 2013	Feb. 13, 2012	Mar. 31, 2013	Mar. 31, 2012	Jun. 30, 2013	Mar. 04, 2013
Class of Stock [Line Items]
Public offering units		1,421,735
Unit issued during period price per unit new issues		$ 6.00
Public offering of units description		Each Unit consisted of one share of the Companys common stock and one warrant to purchase one half of a share of the Companys common stock.
Issuance of common stock and warrants in public offering (In shares)		1,421,735
Shares of common stock issuable upon exercise of warrants		781,955
Net proceed from offering common stock and warrants	$ 4,600,000	$ 7,400,000
Issuance of common for redemption of Warrants				23,127
Closing price of shares						$ 2.39
Stock issued during period, shares, new issues			119,370
Accrued bonuses			$ 285,300
Stock issued during period, shares, other	248,147
Share price	$ 2.095				$ 2.00

Inventories (Detail) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Inventory Disclosure [Line Items]
Purchased components	$ 252,544	$ 187,567
Finished goods	501,400	646,959
Inventories	$ 753,944	$ 834,526

Accrued Expenses (Detail) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Schedule of Accrued Liabilities [Line Items]
Technology fees	$ 450,000	$ 450,000
Professional services	194,576	248,759
Clinical study obligations	104,000	24,490
Sales taxes	33,334	62,385
Supplier obligations	0	105,132
Other	279,258	58,077
Accrued expenses	$ 1,061,168	$ 948,843

Commitments and Contingencies - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2013
Commitments and Contingencies Disclosure [Line Items]
Lease expiration date	Mar. 31, 2015
July 2013 through March 2015
Commitments and Contingencies Disclosure [Line Items]
Base rent	$ 52,917

Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Assets:
Cash equivalents	$ 4,193,007	$ 519,242
Total	4,193,007	519,242
Liabilities:
Common stock warrants	2,855,209
Total	2,855,209
Fair Value, Inputs, Level 1
Assets:
Total	4,193,007	519,242
Liabilities:
Total	0
Fair Value, Inputs, Level 1 \| Fair Value, Measurements, Recurring
Assets:
Cash equivalents	4,193,007	519,242
Liabilities:
Common stock warrants	0
Fair Value, Inputs, Level 2
Assets:
Total	0	0
Liabilities:
Total	0
Fair Value, Inputs, Level 2 \| Fair Value, Measurements, Recurring
Assets:
Cash equivalents	0	0
Liabilities:
Common stock warrants	0
Fair Value, Inputs, Level 3
Assets:
Total	0	0
Liabilities:
Total	2,855,209
Fair Value, Inputs, Level 3 \| Fair Value, Measurements, Recurring
Assets:
Cash equivalents	0	0
Liabilities:
Common stock warrants	$ 2,855,209

Fair Value Measurements - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended
	Feb. 13, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 04, 2013
Fair Value Disclosures [Line Items]
Share price		$ 2.00		$ 2.00		$ 2.095
Exercise price		$ 2.00		$ 2.00
Risk free interest rate	0.85%			1.41%
Expected term	5 years			4 years 11 months
Expected volatility	73.50%			74.10%
Net loss		$ (1,345,830)	$ (2,772,128)	$ (3,599,245)	$ (5,524,463)
Common stock warrants liability		$ 2,855,209		$ 2,855,209

Summary of changes in the fair value of the company's level 3 financial liabilities (Details) (USD $)	6 Months Ended
	Jun. 30, 2013
Summary of changes in the fair value [Line Items]
Balance at December 31, 2012	$ 0
Initial fair value of warrants	4,011,205
Change in fair value of warrant liability	(1,155,996)
Balance at June 30, 2013	$ 2,855,209

Credit Facility - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2013	Jan. 28, 2013
Line of Credit Facility [Line Items]
Revolving credit facility, maximum borrowing capacity	$ 2,500,000	$ 7,500,000
Credit Facility expiration date	Jan. 31, 2014
Amount available for borrowing	2,275,000
Credit Facility limit restricted to support letter of credit	$ 225,000
Prime Rate
Line of Credit Facility [Line Items]
Interest rate over prime rate	0.50%

Stockholders’ Equity - Additional Information (Detail) (USD $)	0 Months Ended		6 Months Ended				0 Months Ended				3 Months Ended	0 Months Ended
	Jun. 04, 2013	Feb. 13, 2012	Jun. 30, 2013	Dec. 31, 2012	Jul. 08, 2013 Series A One Convertible Preferred Stock	Jun. 04, 2013 Series A One Convertible Preferred Stock	Jun. 04, 2013 Series A Two Convertible Preferred Stock	Jul. 08, 2013 Series A Two Convertible Preferred Stock	Jun. 30, 2013 Convertible Preferred Stock	Dec. 31, 2012 Convertible Preferred Stock	Jun. 30, 2013 Warrants	Feb. 13, 2012 Placement Agent	Feb. 13, 2012 Public Offering	Feb. 13, 2012 Minimum Public Offering
Public Offering Of Common Stock and Warrants [Line Items]
Public offering of units		1,421,735
Public offering of units, price per unit		$ 6.00
Public offering of units, description		Each Unit consisted of one share of the Companys common stock and one warrant to purchase one half of a share of the Companys common stock.
Shares of common stock issued in public offering		1,421,735
Shares of common stock issuable upon exercise of warrants		781,955					2,365,934					71,087	710,868
Net proceed from offering common stock and warrants	$ 4,600,000	$ 7,400,000
Period over which warrants become exercisable														180 days
Number of warrants to be exercised to acquire one common share													2
Warrant exercise price							$ 2.00					$ 7.50	$ 6.90
Warrant exercise price Rate												125.00%	115.00%
Common stock warrants issued to placement agent as a percentage of total units sold												5.00%
Fair Value of Warrants		2,400,000									4,000,000
Expected volatility		73.50%	74.10%								73.60%
Risk free interest rate		0.85%	1.41%								1.05%
Expected life		5 years	4 years 11 months
Stock issued during period, shares, other	248,147
Share price	$ 2.095		$ 2.00								$ 2.60
Preferred stock, issued					266,564	1,066.254	3,370.51	10.475	4,436.764	0
Preferred stock, par value			$ 0.001	$ 0.001		$ 1,000	$ 1,000
Gross proceeds from issuance or sale of equity	5,000,000
Convertible preferred stock, Terms of conversion	2.095
Preferred stock, Discount on shares	766,900
Class of warrant or right change in fair value											2,900,000
Decrease in fair value of warrants											$ 1,100,000
Class of warrant or right, Number of securities called by warrants or rights	2,365,934
Class of warrant or right, Exercise price of warrants or rights						$ 2.00	$ 2
Common stock, issued			2,505,071	2,140,871	127,238			5,000
Exercise Price			$ 2.00								$ 2.00

Reverse Stock Split - Additional Information (Detail)	0 Months Ended	6 Months Ended
Reverse Stock Split - Additional Information (Detail)	Feb. 15, 2013	Jun. 30, 2013
Stockholders equity note reverse stock split conversion ratio	1-for-6
Common stock outstanding immediately prior to reverse stock split		12,845,228
Adjusted outstanding shares on reverse stock split		2,140,871

Accrued Compensation and Expenses - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Accrued Compensation and Expenses [Line Items]
Severance charges	$ 429,178	$ 0

Comprehensive Loss - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Other Comprehensive Income Loss [Line Items]
Other Comprehensive Income (Loss), Net of Tax	$ 0	$ 0